Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor

BioSpace

With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech executives penned a letter imploring the Trump administration to “restore re

Policy / PricingRare DiseaseRead full story